期刊文献+

GDF15在前列腺癌及其癌前病变中的表达和意义 被引量:1

Expression of GDF15 in prostatic carcinoma and intraepithelial neoplasia
下载PDF
导出
摘要 目的探讨前列腺癌及癌前病变组织中GDFl5基因的表达情况及临床意义。方法运用组织芯片技术及免疫组化SP法检测72例前列腺癌组织(PCa组,其中Gleason评分5~7分42例,〉7分30例)、22例高级别前列腺上皮内瘤组织(PIN组)、23例良性前列腺增生组织(BPH组)中GDFl5蛋白的表达和分布情况。结果GDFl5在PCa、PIN、BPH组中的阳性表达率分别为95.8%、727%、87%;其在PCa及PIN组织中的阳性表达率均明显高于BPH组织(均P〈0.05),而且在PCa组织中的阳性表达率也明显高于PIN组织(P〈0.05)。中分化PCa组织中GDFl5阳性表达率为92.9%(39/42),低分化PCa组织中为100.0%(30/30),差异无统计学意义(P〉0.05)。结论GDFl5在前列腺癌中高表达,对前列腺癌的发生、发展可能起到重要作用。检测GDFl5在正常前列腺组织、高级别PIN、前列腺癌组织中的表达情况。有助于病理学上早期诊断前列腺癌。 Objective To investigate the expression and clinic significance of GDF15 protein in prostatic intraepithelial neoplasia and adenocarcinoma. Methods GDF15 protein expression was evaluated in 73 cases of prostate carcinoma, 22 high grade prostatic intraepithelial neoplasia (PIN) and 23 benign prostatic hyperplasis (BPH) by immunohistochemistry SP and tissue microarray. Results The positive rates of GDF15 protein were 95.8% (69/72), 72.7% (16/22) and 8.7% (2/23) in prostate carcinoma, high grade PIN and BPH, respectively (P〈0.05). There was a significant difference in GDF15 expression between high grade PIN and BPH (P〈0.05), but no significant difference between moderate differentiated prostatic cancer (the Gleason histological score:5-7) and the lower one (the Gleason histological score: 8-10)(P〉0.05 ). Conclusion GDE15 may be involved in the development of prostatic carcinoma and might be used for early diagnosis of prostatic carcinoma.
出处 《浙江医学》 CAS 2011年第8期1162-1164,共3页 Zhejiang Medical Journal
基金 浙江省医药卫生科研基金资助项目(20058053)
关键词 前列腺癌 GDF15 组织芯片 免疫组织化学 Prostatic carcinoma GDF15 Tissue microarray Immunohistochemistry
  • 相关文献

参考文献1

二级参考文献9

  • 1Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis a new significant and independent prognostic indicator in early-stage breast carcinoma[J]. Nat Cancer Ins, 1992,84(24): 1875 - 1887.
  • 2Wang JM, Kumar S, van Agthoven A, et al. Irradiation induces upregulation of E9 protein (CD105) in human vascular endothelial cells[J]. Int J Cancer, 1995,62(6) :791 - 796.
  • 3Brennan PA. The action and interactions of nitric oxide in solide tumors[J]. Eur J Surg Oncol,2000,26(5) :434 - 437.
  • 4Cianchi F, Cortesini C, Fantappie O, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer[J]. Clin Cancer Res, 2004,10(8): 2694 - 2704.
  • 5Palayoor ST. Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-lalpha and HIF-2alpha in prostate cancer cells[J].Clin Cancer Res,2003,9(8):3150- 3157.
  • 6Kononen J, Bubendor L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens[J]. Nat Med,1998,4(7):844-847.
  • 7Pacifico MD, Grover R, Richman P, et al. Validation of tissue microarray for the immunohistochemical profiling of melanoma [J].Melanoma Res,2004,14(1) :39 - 42.
  • 8Bubendorf L, Necito A, Mech H, et al. Tissue microarray (TMA) technology:miniaturized pathology archives for high throughput in situ studies[J].J Pathol, 2001,195(1):72 - 79.
  • 9周小鸽,张劲松,张小平,张野,Kristian Sandvej,Stephen J Hamilton-Dutoit.组织芯片[J].中华病理学杂志,2002,31(1):70-72. 被引量:85

共引文献13

同被引文献14

  • 1Marrelli D,Pedrazzani C, Roviello F. Gastric cancer prognosis: strong correlation between incidence and survival[J]. Ann Surg Oncol,2010,17(1):340-341.
  • 2Zhao ZQ, Yang S, Lu HS. Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival[J]. Mol Med Re- port,2012,5(2) :415-419.
  • 3Lazar D,Taban S,Dema A, et al. Gastric cancer: the correlation between the clinicopathological factors and patients" survival (I) [J]. Rom J Morphol Embryol,2009,50(1):41-50.
  • 4Zimmers TA,Jin X, Hsiao EC,et al. Growth differentiation factor-15 :induction in liver injury through p53 and tumor necrosis factor-independent mechanisms [J]. J Surg Res, 2006,130(1) : 45-51.
  • 5Feng MY,Wang K, Shi QT, et al. Gene expression profiling in TWIST-depleted gastric cancer cells[J]. Anat Ree (Hoboken), 2009,292(2) :262-270.
  • 6Zimmers TA,Jin X,Gutierrez JC,et al. Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis[J]. J Cancer Res Clin Oncol,2008,134(7):753-759.
  • 7Breit SN,Carrero JJ,Tsai VW, et al. Maerophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease. Nephrol[J]. Dial Transplant, 2012,27 ( 1 ) : 70-75.
  • 8Liu L,Zhou CC,Zhou LQ, et al. Functional FEN1 genetic variants contribute to risk of hepatocellular carcinoma, esophageal cancer,gastric cancer and colorectal cancer[J]. Carcinogenesis, 2012,33(1):119-123.
  • 9Jae YL, Sun OY, Soon WH, et al. Abstract 4540:Pyruvate kinase M2 (PKM2) associated with poor prognosis in gastric signet ring cell carcinoma[J]. Cancer Res,2012,72(4):4540.
  • 10Begnami MD,Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric careinomas: HER2 and HER3 are predictors of poor outcome[J]. Clin Oncol,2011,29(8):3030-3036.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部